Vaccibody AS represents a set of core values and corporate philosophy that drives its operations. The company places a strong emphasis on innovation, striving to develop cutting-edge solutions in the field of immunotherapy. With a focus on precision medicine, Vaccibody AS aims to enhance patient outcomes by tailoring treatments to individual needs. The company is committed to scientific excellence, fostering collaborations to advance research and development efforts. Vaccibody AS also upholds principles of transparency and ethical conduct, ensuring the highest standards of integrity throughout its operations. Overall, the company's values and corporate philosophy revolve around pushing the boundaries of medical innovation to address unmet needs in healthcare while prioritizing patient-centricity.

Vaccibody AS is primarily present in Norway, with its headquarters located in Oslo. As a biotechnology company, Vaccibody AS focuses on developing innovative immunotherapies and targeted treatments for various diseases. While primarily based in Norway, Vaccibody AS also collaborates with academic institutions, research organizations, and pharmaceutical companies worldwide to advance its technologies and reach a broader global audience. With its dedication to revolutionize healthcare solutions, Vaccibody AS is committed to making a positive impact on the lives of patients not only in Norway but also around the globe.

Vaccibody AS, a leading biotechnology company, has achieved several significant milestones. The company successfully completed a Phase I clinical trial for its individualized therapeutic cancer vaccine, VB10.NEO. This trial demonstrated the vaccine's safety and ability to induce immune responses against cancer-specific mutations. Vaccibody AS also entered into a strategic collaboration with Genentech, a member of the Roche Group, to develop personalized cancer vaccines using Vaccibody's proprietary platform. Additionally, the company secured a research grant from the European Union's Horizon 2020 program to further advance its innovative pipeline. These accomplishments highlight Vaccibody AS's dedication towards revolutionizing cancer treatment through the development of highly targeted and personalized therapies.

Vaccibody AS is a Norwegian biotechnology company specializing in the development of therapeutic vaccines to treat cancer. Founded in 2006, the company has a rich history in the field of innovative immunotherapies. Vaccibody AS aims to harness the body's immune system to fight cancer cells effectively. With a focus on precision medicine, the company has developed a versatile and scalable platform technology known as the Vaccibody Vaccine technology. This technology has shown promising results in preclinical and clinical trials, demonstrating its potential in improving patient outcomes. Vaccibody AS continues to advance its research and development efforts to address unmet medical needs and make meaningful contributions to the field of cancer therapeutics.

The main competitors of Vaccibody AS in the market include companies such as Genocea Biosciences, Moderna Therapeutics, BioNTech SE, and Inovio Pharmaceuticals.

Vaccibody AS is primarily active in the biotechnology and pharmaceutical industries.

The business model of Vaccibody AS is focused on the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases. Vaccibody utilizes a unique platform technology known as the Vaccibody Virus-Like Particle (VLP) platform, which enables the design and production of specifically targeted vaccines. By leveraging this platform, Vaccibody aims to create personalized and precise therapeutics that activate the body's immune system to fight against these diseases. Through continuous research and collaboration, Vaccibody AS aims to revolutionize the field of immunotherapy and provide effective treatments for patients.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Nykode Therapeutics A.

KUV:tä ei voida tällä hetkellä laskea Nykode Therapeutics A osalta.

AlleAktien Laatuscore Nykode Therapeutics A on 2/10.

odotettu Nykode Therapeutics A liikevaihto on 510 000,00 USD.

odotettu Nykode Therapeutics A voitto on −23,32 milj. USD.

Vaccibody AS is a Norwegian biotechnology company specializing in the development of personalized cancer vaccines. The company's business model is based on utilizing its proprietary technology platform, which is based on DNA molecules called plasmids. The company offers a wide range of products and services, including: 1. Vaccibody platform: Vaccibody's DNA platform has been developed to create tailor-made vaccines for fighting cancer and infectious diseases. The platform utilizes the body's own immune response to combat tumor cells and harmful pathogens and reduce disease symptoms. 2. Vaccines: Vaccibody's vaccines can be customized for each individual patient to trigger an optimal immune response against the tumor or disease-causing virus. The vaccine is made from the patient's genetic material, allowing for personalized therapy. 3. Drug delivery: Vaccibody has also developed a unique targeted drug delivery method. The platform utilizes the ability of antibodies to recognize specific cells in the body to enable targeted drug delivery. This approach reduces the dosage required for effective therapy and therefore minimizes side effects. 4. Partnerships: Vaccibody collaborates with leading pharmaceutical and biotech companies to accelerate the development and commercialization of their technology platform. This collaboration includes the development of vaccines and drugs based on the Vaccibody platform, as well as licensing and selling patents and technologies. Overall, Vaccibody's business model aims to develop personalized therapy for cancer and infectious diseases based on the body's own immune response. By utilizing its proprietary technology platform and collaborating with partners in the pharmaceutical industry, the development and commercialization of vaccines and drugs are expedited. The output is: Vaccibody AS is a Norwegian biotechnology company specializing in the development of personalized cancer vaccines. The company's business model is based on utilizing its proprietary technology platform, which is based on DNA molecules called plasmids.

Nykode Therapeutics A maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Nykode Therapeutics A:lle tai yhtiö ei maksa osinkoa.

Nykode Therapeutics A:n ISIN on NO0010714785.

Nykode Therapeutics A:n WKN on A2PZ5J.

Nykode Therapeutics A:n tunnus on NYKD.OL.

Viimeisen 12 kuukauden aikana Nykode Therapeutics A maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Nykode Therapeutics A maksanee ennusteiden mukaan 0 USD osingon.

Nykode Therapeutics A:n tämänhetkinen osinkotuotto on .

Nykode Therapeutics A maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Nykode Therapeutics A maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Nykode Therapeutics A kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Nykode Therapeutics A osingon 12.6.2025, jonka suuruus on 1 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 27.5.2025.

Viimeisin osinko maksettiin 12.6.2025.

Vuonna 2024 Nykode Therapeutics A maksoi 0 USD osinkoina.

Nykode Therapeutics A:n osingot maksetaan USDssa.